Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program

Julia Cave Arbanas; Cheryl L Damberg; Mei Leng; Nina Harawa; Catherine A Sarkisian; Bruce E Landon; John N Mafi

doi:10.1001/jamainternmed.2023.1749

Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program

JAMA Intern Med. 2023 Aug 1;183(8):885-889. doi: 10.1001/jamainternmed.2023.1749.

Authors

Julia Cave Arbanas¹, Cheryl L Damberg², Mei Leng¹, Nina Harawa^{1

3}, Catherine A Sarkisian^{1

4}, Bruce E Landon⁵, John N Mafi^{1

2}

Affiliations

¹ Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at University of California, Los Angeles.
² RAND Corporation, Santa Monica, California.
³ Fielding School of Public Health at University of California, Los Angeles.
⁴ VA Greater Los Angeles Healthcare System Geriatrics Research & Clinical Center (GRECC), Los Angeles, California.
⁵ Harvard Medical School and the Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

No abstract available

Plain language summary

This cross-sectional cost analysis uses data from the 2018 Health and Retirement Study to estimate the potential future Medicare spending and beneficiary costs for lecanemab.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Aged
Costs and Cost Analysis
Health Expenditures*
Humans
Medicare*
United States

Substances

lecanemab

Plain language summary

Publication types

MeSH terms

Substances

Grants and funding